SEC Form 4 · accession 0000950142-17-000081
MELINTA THERAPEUTICS, INC. /NEW/ · MLNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dov A Goldstein M.D.
Director
Period of report
Jan 5, 2017
Accepted (ET)
Jan 6, 2017 · 5:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001461993
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 5, 2017 | S | 500,000 | $3.20 | D | 693,060 | I | By Aisling Capital II, LP |
| Common StockF3,F2 | Jan 6, 2017 | S | 437,600 | $3.64 | D | 255,460 | I | By Aisling Capital II, LP |
| Common Stock | holding | — | — | — | 95 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 to $3.23, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.
- F2The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.50 to $3.75, inclusive.